$8 Billion Verdict: Jury decides J&J should pay in Risperdal case
October 9, 2019: Late yesterday a Philadelphia jury rendered an $8 billion punitive damages verdict against pharmaceutical company Johnson & Johnson for illegally marketing the antipsychotic drug Risperdal, putting young boys at risk for developing female-sized breast tissue. The condition, gynecomastia, is irreversible. “The conduct the jury saw in the courtroom was clear and convincing that J&J disregarded the […]
J&J Settles Days Before Risperdal Trial
After years of litigation and several court losses for harm caused by Risperdal, Johnson & Johnson’s legal team agreed to settle the suit of a young boy from Mississippi who claims he developed female-like breasts after taking the drug Risperdal. The plaintiff began taking Risperdal in 2004 after he was tentatively diagnosed with bipolar disorder. J&J […]
Plaintiff wins Bellwether Xarelto Case in Philadelphia Court
A Philadelphia jury awarded Lynn Hartman $27.8 million after finding drug manufacturers Johnson & Johnson and Bayer failed to warn about the dangers of their blood thinning drug Xarelto. The verdict includes $26 million in punitive damage, which juries award to plaintiffs when they believe the defendant acted egregiously. This bellwether case tried in Pennsylvania […]
Sheller hits #1 Top 50 Verdicts in Pennsylvania for 2016
Sheller PC’s $70 Million Risperdal win hits #1 on the Top 50 Verdicts in Pennsylvania in 2016. In the case A.Y., Pro Ami v. Janssen Pharmaceuticals, Inc., a jury found for an autistic Tennessee boy who grew female-like breasts after taking the antipsychotic drug Rispderal. The unprecedented $70 Million verdict in damages for physical disfigurement and emotional […]
Sheller on “Full Measure” TV: Update
The television program “Full Measure with Sharyl Attkisson” updated their segment “Bitter Pill” that featured the story of the Sheller firm’s Risperdal litigation. The updated report included the recent $70 million verdict. See the updated broadcast of “Bitter Pill” with the interview of Stephen Sheller here: http://fullmeasure.news/news/politics/bitter-pills-08-02-2016 See the Sheller.com previous post on the segment […]
$70M Risperdal Verdict
In the Philly Inquirer July 2, 2016: Philadelphia jury pins $70m verdict on Janssen for its Risperdal drug A Philadelphia jury found Friday that the antipsychotic drug Risperdal caused a Tennessee boy to grow breasts and imposed a $70 million verdict on its manufacturer, Janssen Pharmaceuticals. Lawyers for the boy argued that scientists for the […]
Sheller Appears on “Full Measure” TV
Attorney Stephen Sheller appeared on the television program “Full Measure’ May 1, 2016 discussing Risperdal gynecomastia cases. Sheller was interviewed by Sharyl Attkisson, who previously covered the Risperdal story with attorney Sheller for CBS news, in a video that has now been watched nearly 60,000 times on the CBS and Sheller YouTube channels. Full Measure is the […]
BREAKING: $1.75M Verdict
A $1.75 million verdict in a Sheller firm antipsychotic drug Risperdal case was awarded today in Pennsylvania in the fourth case alleging Johnson & Johnson failed to warn of the risks of gynecomastia, the development of female-like breasts in boys and young men. The jury found the drug was a “substantial factor” in causing a […]
News: Trials Begin October 2015
Sheller, P.C. law firm Risperdal cases continue, with trials beginning October, 2015. From the daily newspaper The Legal Intelligencer: “A second wave of trials in the Risperdal mass tort has been scheduled for October, and several more cases are gearing up for trials in the spring. Two trials against Janssen Pharmaceuticals, the maker of the […]
Risperdal News: Sheller Quoted in Toronto Star
Stephen Sheller was quoted in a July 31, 2015 article discussing Risperdal research that was “manipulated by a drug company and understated the risks of a powerful antipsychotic used to treat kids with behavioural problems.” In the news story, pediatrician Denis Daneman says there was no intent on his part to exclude “significant results” from […]
